Practice informative: Risk of Radiation Pneumonitis in Patients Receiving Osimertinib and Thoracic Radiotherapy (N=41) G2+ in 19.5% (including 1 death), median onset 4.7 months (range: 3.1–6.9). Pneumonitis associated with increased lung V20 and V5. #LCSM redjournal.org/article/S0360-…